Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Basic and clinical studies on cefmenoxime in pediatric field].

S Iwata, Y Iwasaki, T Kanemitsu

    The Japanese Journal of Antibiotics
    |October 1, 1982
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.

    Lung cancer (Amsterdam, Netherlands)·2019
    Same author

    Appropriate management of high-flow priapism based on color Doppler ultrasonography findings in pediatric patients: four case reports and a review of the literature.

    Journal of pediatric urology·2019
    Same author

    FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2017
    Same author

    A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2017
    Same author

    Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection.

    ESMO open·2016
    Same author

    Anatomical versus non-anatomical resection for hepatocellular carcinoma.

    The British journal of surgery·2015

    Cefmenoxime (CMX) demonstrates potent antibacterial activity against common pediatric pathogens and shows promising clinical efficacy in children with infectious diseases. Pharmacokinetic studies reveal favorable blood concentrations and a short half-life, with minimal side effects observed.

    Area of Science:

    • Pediatric Infectious Diseases
    • Pharmacology
    • Antibiotic Therapy

    Background:

    • Cefmenoxime (CMX) is a cephalosporin antibiotic.
    • Pediatric infections require effective and safe treatment options.

    Purpose of the Study:

    • To evaluate the antibacterial activity, pharmacokinetics, and clinical efficacy of cefmenoxime (CMX) in pediatric patients.
    • To compare the efficacy of CMX with another cephalosporin, CEZ.
    • To assess the safety profile of CMX in children.

    Main Methods:

    • In vitro testing of CMX antibacterial activity against clinical isolates.
    • Pharmacokinetic analysis of CMX blood concentrations after intravenous administration (bolus and infusion).
    • Clinical evaluation of CMX in 10 children with infectious diseases, including bacteriological assessment.

    Related Experiment Videos

    Main Results:

    • CMX exhibited stronger activity than CEZ against Gram-negative bacteria (E. coli, Salmonella, K. pneumoniae, P. mirabilis, S. marcescens, P. aeruginosa), while CEZ was more active against Staphylococcus aureus.
    • Intravenous administration of CMX resulted in measurable blood concentrations with half-lives of approximately 1 hour.
    • All 10 pediatric patients showed complete or partial clinical response, with successful bacterial eradication in 3 cases. Side effects were mild and infrequent.

    Conclusions:

    • Cefmenoxime (CMX) is an effective antibiotic for treating pediatric infections caused by susceptible bacteria.
    • CMX possesses favorable pharmacokinetic properties and a good safety profile in children.
    • Further investigation into CMX use in pediatric populations is warranted.